CLINICAL_TRIALS
trial_result
· 2014-01-14
Clinical Trial Update: CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML) [Phase 2]
Summary
A Phase 2 trial evaluating CLAG plus Gleevec (imatinib) in relapsed or refractory acute myeloid leukemia has completed, with results posted in January 2014.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2014-01-14